Gland Pharma Ltd Share Price
(GLAND)
₹1412.9
as on 04:01PM, 29 Apr 2025
Gland Pharma Performance
Day's Low
Day's High
₹1,401.6Day's Price Range₹1,44052 Week's Low
52 Week's High
₹1,277.852-Week Price Range₹2,220.95
| Returns % | |
| 1 Month Return | -9.05 % |
| 3 Month Return | -6.21 % |
| 1 Year Return | -17.43 % |
| Market Stats | |
| Previous Close | ₹1,413.10 |
| Open | ₹1,422.00 |
| Volume | 1.46L |
| Upper Circuit | ₹1,695.70 |
| Lower Circuit | ₹1,130.50 |
| Market Cap | ₹23,278.43Cr |
Gland Pharma Fundamentals
P/E Ratio
33.04
PEG Ratio
11.97
Market Cap
₹23,278.43 Cr
P/B Ratio
3.37
EPS
46.9
Dividend Yield
1.09
Sector
Pharmaceuticals
ROE
12.31
Mutual Fund Holdings of Gland Pharma
Gland Pharma Analyst Rating
based on 11 analysts
41.67%
Buy
8.33%
Hold
50.00%
Sell
Based on 11 analysts offering long term price targets for Gland Pharma. An average target of ₹1712.91
Source: S&P Global Market Intelligence
Gland Pharma Share analysis
Gland Pharma price forecast by 11 analysts
Upside of21.23%
High
₹3120
Target
₹1712.91
Low
₹1162
Gland Pharma target price ₹1712.91, a slight upside of 21.23% compared to current price of ₹1412.9. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma revenue growth forecast
Expected growth rate Q1, FY2027:26.24%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma EPS growth forecast
EPS estimate Q1, FY2027:50.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Gland Pharma Ltd
Gland Pharma Updates RTA Contact Details Post-Rebranding - 24 Apr, 2025
Gland Pharma Limited has updated the contact details of its Registrar and Share Transfer Agent, rebranding from Link Intime India Private Limited to MUFG Intime India Private Limited. This change is essential for shareholders and stakeholders for effective communication and service requests.Gland Pharma Secures SEBI Compliance Certificate - 10 Apr, 2025
Gland Pharma Limited announced the receipt of a SEBI compliance certificate for Q1 2025, ensuring transparency and regulatory adherence. However, the stock has faced recent declines alongside broader market pressures.Gland Pharma Overview: Market Position and Performance - 05 Apr, 2025
Gland Pharma Ltd specializes in injectable formulations and complex drug molecules. With a market cap of Rs 24,306 crores, its PE ratio is lower than the industry average. The stock is down 33% from its 52-week high of Rs 2,220.95, currently at Rs 1,475. ROE and ROCE stand at 9.26% and 13.58%, respectively.Gland Pharma Shares Decline Amid Tariff Concerns - 04 Apr, 2025
Gland Pharma shares fell 5.29% to ₹1,477.00 following President Trump's hints at potential pharmaceutical tariffs. Analysts warn this could pressure margins and impact revenue from the U.S. market.Gland Pharma Gains on Tariff Exemption and FDA Approval - 03 Apr, 2025
Gland Pharma's stock saw positive movement following USFDA approval for Acetaminophen Injection and tariff exemptions for pharmaceuticals, boosting investor confidence.Gland Pharma Announces Trading Window Closure - 28 Mar, 2025
Gland Pharma Limited has announced the closure of its trading window from March 29, 2025, until 48 hours after its financial results are declared, in compliance with SEBI regulations.Gland Pharma Explores Majority Stake Sale Discussions - 27 Mar, 2025
Gland Pharma, known for developing generic injectables, is reportedly in talks with various global funds for a potential majority stake sale, valuing the company at $3 billion. This follows its acquisition by Shanghai Fosun Pharmaceutical in 2016 for $1.3 billion.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 143.76 Cr → 204.69 Cr (in ₹), with an average increase of 16.1% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 5.04% to 6.90% in Mar 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 192.9%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 69.4%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 32.37% to 31.16% in Mar 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 1.46K Cr → 1.44K Cr (in ₹), with an average decrease of 1.6% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.33% to 7.99% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, GLAND stock has moved down by -9.0%
Gland Pharma Financials
Gland Pharma Index Inclusions
Gland Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 6.9% | 0.00 | |
| Mutual Funds | 31.16% | 0.00 | |
| Retail Investors | 7.99% | 0.00 | |
| Others | 2.11% | 0.00 |
Gland Pharma Key Indicators
Gland Pharma Valuation
Gland Pharma in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (33.04x)
April 29, 2025
Industry (54.77x)
April 29, 2025
Highest (67.14x)
August 12, 2021
Gland Pharma Earnings and Dividends
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit jumped 6.69% since last year same period to ₹204.69Cr in the Q3 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated 25.17% jump in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.42%.
Read More about Dividends
Gland Pharma Technicals Summary
Bearish
Neutral
Bullish
Gland Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
Gland Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹23,278.43 Cr | -4.47% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| HOLD | ₹1,62,148.21 Cr | 32.36% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,12,450.22 Cr | 36.67% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,281.13 Cr | -1.98% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| BUY | ₹1,24,497.77 Cr | 32.29% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
About Gland Pharma
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Revenue: ₹1,384.05Cr as on December 2024 (Q4 24)
Net Profit: ₹204.69Cr as on December 2024 (Q4 24)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Gland Pharma Ltd
What is Gland Pharma Ltd price today?
Gland Pharma Ltd share price today stands at ₹1412.9, Open: ₹1422, Previous Close: ₹1413.1, High: ₹1440, Low: ₹1401.6, 52 Week High: ₹2220.95, 52 Week Low: ₹1277.8.
How to Buy Gland Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Gland Pharma Ltd shares
What are today's traded volumes of Gland Pharma Ltd?
Today's traded volume of Gland Pharma Ltd(GLAND) is 1.46L.
What is today's market capitalisation of Gland Pharma Ltd?
Today's market capitalisation of Gland Pharma Ltd(GLAND) is ₹23278.43Cr.
What is the 52 Week High and Low Range of Gland Pharma Ltd?
How much percentage Gland Pharma Ltd is down from its 52 Week High?
Gland Pharma Ltd (GLAND) share price is ₹1412.9. It is down -36.38% from its 52 Week High price of ₹2220.95
How much percentage Gland Pharma Ltd is up from its 52 Week low?
Gland Pharma Ltd (GLAND) share price is ₹1412.9. It is up 10.57% from its 52 Week Low price of ₹1277.8